“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

Astex Pharmaceuticals


Astex Pharmaceuticals products

INQOVI (ASTX727 – decitabine + cedazuridine oral combination)
Indication: Treatment of intermediate- and high-risk myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML); an oral hypomethylating agent that's bioequivalent to IV decitabine.

Kisqali (ribociclib)
Indication: CDK4/6 inhibitor for hormone receptor–positive (HR+), HER2-negative advanced breast cancer. Discovered in partnership with Novartis.

Balversa (erdafitinib)
Indication: FGFR inhibitor for metastatic urothelial carcinoma. Originated from Astex’s collaboration with Janssen Pharmaceuticals.

Truqap (capivasertib)
Indication: AKT inhibitor approved in combination with fulvestrant for HR+, HER2-negative metastatic breast cancer with PIK3CA, AKT1, or PTEN alterations. Developed via collaboration with AstraZeneca and research partners.

Other Astex Pipeline Assets in Clinical and Preclinical Development

  • ASTX029 (beroterkib) – ERK1/2 inhibitor targeting solid tumors.

  • ASTX295 – MDM2 antagonist for solid tumors.

  • Tolinapant (ASTX660) – Dual IAP antagonist aimed at T-cell lymphomas.

  • SHP2 inhibitors, p53-targeting compounds, and KRAS-targeted therapies—all under active oncology exploration.



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)